A Study of IMR-687 in Subjects With Beta Thalassemia

NCT04411082 ↗

Phase 2 Terminated 122 enrolled Cardurion Pharmaceuticals, Inc. Imara, Inc. · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

A Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects with Beta Thalassemia

Timeline

Start: 2020-10-16
Primary completion: 2022-03-11
Completion: 2022-05-04

Outcome

Outcome not reported

Stopped: “IMR-BTL-201demonstrated that while IMR-687 was generally well-tolerated, it failed to show any meaningful benefit in transfusion burden or improvement in most disease-related biomarkers. So, the sponsor has decided to discontinue this study”

Publications

Foong WC, Loh CK, Ho JJ, Lau DS. Foetal haemoglobin inducers for reducing blood transfusion in non-transfusion-dependent beta-thalassaemias. Cochrane Database Syst Rev. 2023 Jan 13;1(1):CD013767. doi: 10.1002/14651858.CD013767.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tovinontrine	Small molecule	—	Oral